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mGX sPLA2 is specifically expressed in late spermatogenic cells and in 
























mGX sPLA2 is released during AR. To further demonstrate that 































































Disruption of the Pla2g10 gene coding for 

































Expression of mGX sPLA2 in mouse spermatogenic cells. (A) Quantitative RT-PCR analysis shows 
that mGX mRNA is expressed in the testis, but only minimally in the epididymis. (B) In situ hybridiza-
tion. Sections of testis from 8-week-old C57BL/6J mice were hybridized with antisense and sense 
probes for mGX. Positive signal for mGX was detected in spermatogenic cells (spermatocytes and 
spermatids, but not spermatogonia) in the seminiferous tubules. Original magnification, ×200. Scale 
bar: 100 μm. (C) Immunohistochemistry. Sections of the testis from 8-week-old C57BL/6J mice were 
stained with anti-mGX antibody or control antibody. Intense staining was found in spermatocytes and 
spermatids in the seminiferous tubules but not in spermatogonia (original magnification, ×200). In 
magnified views, scattered signals with crescent and elongated shapes were evident in spermato-
cytes and spermatids, suggesting labeling in the acrosomal area. (D) Spermatozoa from caudae 
epididymis were stained with anti-mGX antibody or control antibodies. Immunofluorescent signal for 
mGX sPLA2 was confined to the sperm head. Note that the staining along the tail was nonspecific, 
since sperm treated with preimmune serum or only secondary antibody were also stained.
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Catalytically active mGX sPLA2 is released from 
sperm during AR. (A) Total amount of mGX pro-
tein measured by TRF-IA in supernatants and 
cell pellets of WT sperm during capacitation (up 
to 90 minutes) and after AR triggered by addition 
of the Ca2+ ionophore A23187 (5 μM) between 60 
and 90 minutes. “Sum” corresponds to the total 
amount of mGX in both fractions at various times. 
(B) Similar assays using mGX–/– sperm, showing 
no mGX signal (sum of supernatant and pellet 
[S + P]) before capacitation (0 minutes) and after 
A23187-induced AR. (C) Total sPLA2 enzymatic 
activity measured using E. coli radiolabeled enzy-
matic assays in supernatants and cell pellets of 
WT sperm during capacitation (n = 5). (D) Similar 
enzymatic assays using mGX–/– sperm, showing 
no variation in sPLA2 enzymatic activity throughout 
capacitation in both fractions (n = 4). (E) sPLA2 
enzymatic activities of supernatants and cell pel-
lets of WT sperm (at 90 minutes + A23187) and of 
recombinant mGX (0.1 nM, n = 2) are inhibited by 
EDTA (20 mM), DTT (10 mM), LY329722 (10 μM), 
and anti-mGX antibody (IgG fraction, 5 μg), but not 
by anti-mGIIA and anti-mGIIF antibodies (n = 2).
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Acrosome-reacted and non-acrosome-reacted sperm treated with mGX 
























The lack of mGX sPLA2 in sperm affects male fertility. (A) The litter 
sizes of intercrosses between male and female mGX-deficient mice 
are lower than those of littermate WT mice. Note that male and female 
mGX–/– mice produced normal litter size when mated with WT C57BL/6J 
mice (B) Pictures of the different stages obtained after IVF at 24 hours: 
unfertilized oocytes; 2-cell embryos (normal development); aborted 
embryos corresponding to oocytes with either multiple and uncon-
trolled divisions or presenting a second polar body (2 PB) but no cell 
division (arrows). Scale bars: 50 μm. (C) Images of embryo devel-
opment 24 hours after fertilization: +/+, WT sperm crossed with WT 
oocytes; –/–, mGX–/– sperm crossed with WT oocytes; arrows show 
unfertilized oocytes and asterisks show aborted embryos. (D) IVFs 
performed with mGX–/– sperm and WT oocytes have a lower rate of 
2-cell embryos and higher rate of aborted embryos compared with 
IVFs performed with sperm from WT (+/+) or heterozygous (+/–) lit-
termates and WT oocytes (n = 11). (E) The low fertilizing potential of 
mGX–/– sperm is rescued by recombinant mGX. IVF was performed 
by mixing WT oocytes with (a) WT sperm from littermates (n = 4); (b) 
mGX–/– sperm (n = 4); or (c) mGX–/– sperm briefly treated with 200 nM 
mGX (treatment for 10 minutes at the end of the capacitation period 
[gray bars, n = 4]). The development of eggs was evaluated after 24 
hours by counting the different stages.
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Endogenous and recombinant mGX sPLA2 both regulate spontaneous 
AR during capacitation. (A) Spontaneous AR of mGX–/– sperm does 
not progress beyond 55 minutes of in vitro capacitation, in contrast to 
WT sperm. Addition of mGX during the last 10 minutes of 90-minute 
capacitation rescues normal spontaneous AR in mGX–/– sperm. Spon-
taneous AR was quantified during capacitation at 10, 55, and 90 min-
utes in mGX+/+ littermate sperm (n = 11) and mGX–/– sperm (n = 6). (B) 
Recombinant mGX sPLA2 is a potent inducer of AR. Dose-response 
curve for AR of noncapacitated WT sperm triggered by mGX (n = 3–8). 
(C) Treatment with mGX sPLA2 (200 nM) for 10 minutes triggers AR 
of both noncapacitated WT sperm (23.7% ± 1.4% to 68.1% ± 2.1% for 
control and mGX-treated sperm, respectively; n = 23) and WT sperm 
capacitated for 90 minutes (46.5% ± 6.3% to 81.8% ± 5.4% for control 
and mGX-treated sperm, respectively; n = 3).
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mGX sPLA2 triggers AR via its catalytic activity and independently of cytosolic Ca2+ rise. (A) Dose-response curves for AR of noncapacitated 
sperm triggered by mGX (n = 3–8), mGX-H48Q (n = 3), and pro-mGX (n = 3). Results are expressed as sPLA2-specific AR, i.e., total AR minus 
spontaneous AR. (B) The specific sPLA2 inhibitor LY329722 (1 μM) blocked the ability of 200 nM mGX to trigger AR of sperm capacitated during 
45 minutes (n = 3). Results correspond to total AR. (C) Loading sperm with 10 μM BAPTA did not modify spontaneous AR (2 left bars, n = 3) and 
mGX-induced AR (2 right bars, t test; NS; n = 3) of sperm incubated in a noncapacitating medium (no BSA). In the presence of BAPTA-AM, the 
difference in the level of AR between nontreated and mGX-treated sperm is statistically significant.
Figure 6
Ultrastructure of the head of mGX sPLA2–treated sperm. (A) Electron micrographs of non-acrosome-reacted sperm treated with 200 nM mGX 
(noncapacitated sperm). (B) Electron micrographs of non-acrosome-reacted control (untreated) sperm (noncapacitated sperm). (C) Acrosome-
reacted sperm (noncapacitated sperm) in the presence of 200 nM mGX presented normal morphological features of sperm undergoing AR: 
fusion between the plasma and acrosomal membrane produced vesiculation (left), and the outer acrosomal membrane was fused with the 
plasma membrane and presented a typical double-hairpin shape at the base of the acrosome (right) or (D) presented early stages of AR, i.e., 
cavitation. Scale bars: 500 nm.
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ing  on  ZP,  ZP-induced AR,  and/or 
sperm-egg fusion.
Discussion
This  study  shows  for  the  first  time 
to our knowledge that mGX sPLA2 is 
present in large amounts in the sperm 










































Blocking endogenous mGX sPLA2 with the specific inhibitor LY329722 impacts both fertility outcome 
and spontaneous AR. (A) Endogenous mGX, secreted during spontaneous AR, controls the yield 
of viable embryos, without changing the rate of fertilization. IVF experiments were performed with 
either control sperm or the same sperm treated throughout capacitation with 1 μM LY329722 (n = 8) 
and unfertilized oocytes. Two-cell embryos and aborted embryos were scored. Inhibiting mGX 
decreases 2-cell embryos and increases aborted embryos. The design of the experiment clearly 
indicates that LY329722 controls the yield of viable embryos by inhibiting endogenous mGX secreted 
during spontaneous AR. (B) The sPLA2 inhibitor LY329722 blocked the late phase of spontaneous 
AR. Spontaneous AR was quantified during capacitation at 10, 55, and 90 minutes in the absence 
or presence of 1 μM LY329722 (n = 10–14). Incubation of sperm with 1 μM LPC during the last 45 
minutes partially rescued the inhibition of spontaneous AR induced by LY329722 (n = 7).
research article











































Exogenous mGX sPLA2 reinforces the effect of endogenous mGX on 
spontaneous AR and improves fertility outcome. (A) Sperm used for 
IVF and briefly pretreated with exogenous mGX present a higher rate 
of spontaneous AR. WT sperm were incubated during the last 10 min-
utes of capacitation with mGX alone (200 nM), LY329722 alone (1 μM), 
or mGX preincubated with LY329722. Only mGX treatment triggered 
significant AR over the untreated condition (n = 6). (B) Recombinant 
mGX controls the yield of viable embryos, without changing the rate of 
fertilization. IVF was performed either with OF1 control sperm or with 
the same sperm briefly treated with 200 nM mGX, and IVF outcome 
was scored (n = 13). Recombinant mGX increases 2-cell embryos 
and decreases aborted embryos. (C) Two-cell embryos obtained with 
mGX-treated sperm developed normally to the blastocyst stage. (D) 
LY329722 blocks the mGX-dependent increase in fertility. IVF was 
performed with either control sperm or the same sperm treated briefly 
with 200 nM mGX or with the same sperm treated with 200 nM mGX 
but preincubated with 1 μM LY329722 (n = 6). (E) The number of 
sperm incubated with oocytes does not impact fertility outcome. IVF 
was performed at 2 different concentrations: 1.5 × 105 and 3 × 105 
sperm (sp) (n = 4).
Figure 9
Addition of LPC during fertilization rescues the fertilization potential of 
sperm treated with sPLA2 inhibitor or anti-mGX antibody during capacita-
tion. (A) IVF experiments were performed with sperm treated or not with 
the sPLA2 inhibitor YM26734 (1 μM) only during the capacitation period. 
LPC (1 μg/ml) was added only during gamete mixing. The approximately 
40% reduction in 2-cell embryo rate measured with YM26734-treated 
sperm (n = 3, P < 0.05) was restored by supplementation with LPC. (B) 
Similar reduction and recovery of IVF were observed with sperm treated 
with anti-mGX antibody (50 μg/ml) during capacitation and LPC added 
during gamete mixing (n = 3, P < 0.05), respectively.
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